As 2025 draws to a close, the Axiom Think Tank is spotlighting how oncology’s standard of care continues to evolve. The past few weeks have brought a surge of pivotal data across tumor types: from major breakthroughs to subtle shifts that could reshape everyday clinical practice.
We’re cutting through the noise to highlight what truly matters - the results that moved the field from incremental to transformational.
FIGURE 1:Where the bar moved most: breast, bladder, and gastric cancer led the charge in redefining standards of care.
FIGURE 2: Key data released this last month, from breast cancer, bladder cancer, and Gastric / GEJ are poised to impact physician choices and are expected to shift the current standard of care
FIGURE 3: Among recent data releases and ESMO discussions, we saw that ADCs continue gaining ground across all tumor types, while bispecific advances remained largely lung-driven but are highly anticipated to have broader impacts as more data becomes available
For full details for the data readouts and trials listed above,
At the Axiom Table, we’re keeping the conversation going - digging into these results and identifying which data truly matter to physicians. To build on these insights, the Axiom Think Tank will be hosting a live discussion with Key Opinion Leaders to explore pan-tumor trends and the overarching implications for oncology.
